You've just added:

Our Impact

How we're advancing cures globally

201

Medicines in the making

71

Institutions supported

39

Companies launched

21

Medicines in the clinic

15

Licenses to pharma

What sets us apart

In addition to receiving funding, every scholar is paired with a results-oriented and mission-focused team from our Therapeutics Development Center. Teams consist of a project manager and experienced pharma and business development advisors with a track record of bringing new drugs to market.

Learn More

Making discoveries partner-ready

Our pipeline represents the best science coming out of academic laboratories. Projects are selected for their innovation and potential for clinical impact. Our team proactively moves them forward to commercial viability and clinical use.

See All Discoveries

Accelerating Scientific Breakthroughs

By concentrating philanthropic, scientific, and business development resources during the high-risk stages of drug development, Harrington ‘de-risks’ therapeutic candidates and positions them for further investment and commercialization.

Learn More

The Latest

See All News
AlveoGene Receives Rare Pediatric Disease Designation (RPDD) from FDA for AVG-002, its Novel, Inhaled Gene Therapy for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency

Press Releases

AlveoGene Receives Rare Pediatric Disease Designation (RPDD) from FDA for AVG-002, its Novel, Inhaled Gene Therapy for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency

Oxford, UK – 15th November 2024 – (or ‘the Company’, www.alveogene.com), a company focused on transforming rare...

Continue Reading
The Oxford-Harrington Rare Disease Centre (OHC) Announces Inaugural 2024 Rare Disease Scholar Award Recipients

Press Releases

The Oxford-Harrington Rare Disease Centre (OHC) Announces Inaugural 2024 Rare Disease Scholar Award Recipients

10 scientists have been selected for OHC’s first annual award to advance academic discoveries into clinical practice for rare diseases

Continue Reading
Former UK Prime Minister David Cameron Joins Oxford-Harrington Rare Disease Centre (OHC) as Chair of its Advisory Council

Press Releases

Former UK Prime Minister David Cameron Joins Oxford-Harrington Rare Disease Centre (OHC) as Chair of its Advisory Council

Lord Cameron will lead international efforts to drive the OHC’s mission of delivering 40 new therapies for rare diseases into clinical trials over the next ten years

Continue Reading
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.